The data strengthens EXPAREL's value proposition to payers and providers, potentially driving formulary adoption and reimbursement in outpatient orthopedic settings. Traders should monitor for increased commercial traction and potential pull-through in ZILRETTA and iovera° given shared commercial infrastructure.
Price Chart
Executive Summary
Pacira BioSciences presented real-world data at AMCP 2026 showing EXPAREL® use in outpatient joint replacement surgeries is associated with lower total healthcare costs and reduced opioid utilization, particularly in patients with low back pain and in teaching hospitals. The findings reinforce EXPAREL's economic value and non-opioid pain management benefits.
Key Facts
- EXPAREL use in THA was associated with lower total healthcare costs at 3 months ($7,332 vs $8,153) and 6 months ($13,022 vs $15,081) compared to non-LB.
- In patients with low back pain, EXPAREL showed significantly lower costs at 6 months ($13,614 vs $18,652) and reduced opioid use by 51 MMEs at 6 months.
- In TKA at teaching hospitals, EXPAREL was linked to statistically significant cost savings at surgical visit, 7 days, and 30 days post-op.
- A 3-year budget model projected $117,868 in cumulative cost savings per 1 million members with EXPAREL vs ropivacaine.
Financial Impact
Projected cumulative cost savings of $117,868 per 1 million members over 3 years; per-member-per-month savings of $0.003
Risk Factors
- Real-world studies show association, not causation, and may not translate into increased prescribing.
- Forward-looking statements are subject to risks including regulatory, commercial execution, and clinical trial uncertainties.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272431 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $25.58 $26.60 | ▲ +3.99% | ▲ +3.39% | $25.21 (−1.45%) |
Jul 22, 2026 10w ago | Press Release | $25.59 $24.36 | ▼ −4.81% | ▼ −7.70% | $25.21 (−1.48%) |
Jun 30, 2026 13w ago | 8-K | $25.37 $26.47 | ▲ +4.34% | ▲ +5.36% | $25.21 (−0.63%) |
Jun 13, 2026 15w ago | Insider Cluster | $22.74 $25.54 | ▲ +12.31% | ▲ +13.06% | $25.21 (+10.86%) |
Jun 4, 2026 17w ago | DEFA14A | $22.75 $25.59 | ▲ +12.48% | ▲ +10.62% | $25.21 (+10.81%) |
Jun 4, 2026 17w ago | 144 | $22.67 $25.39 | ▲ +12.00% | ▲ +13.37% | $25.21 (+11.20%) |
Jun 1, 2026 17w ago | DEFA14A | $22.25 $25.03 | ▲ +12.49% | ▲ +14.06% | $25.21 (+13.30%) |
May 27, 2026 18w ago | DEFA14A | $23.68 $25.24 | ▲ +6.59% | ▲ +9.73% | $25.21 (+6.46%) |
May 26, 2026 18w ago | DEFA14A | $24.04 $24.37 | ▲ +1.37% | ▲ +3.27% | $25.21 (+4.87%) |
May 20, 2026 19w ago | DEFA14A | $23.48 $22.72 | ▼ −3.24% | ▼ −3.57% | $25.21 (+7.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access